









Markets
/
Stocks
/
nasdaq-apls
/

Apellis Pharmaceuticals Inc

APLS

16.970USD

-0.670-3.80%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

835.89MMarket Cap

95.62P/E TTM



Apellis Pharmaceuticals Inc

16.970

-0.670-3.80%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Apellis Pharmaceuticals Inc

Currency: USD Updated: 2026-03-27

Key Insights

Apellis Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 53 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 33.50.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Apellis Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

53 / 157

Overall Ranking

142 / 4542

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Apellis Pharmaceuticals Inc Highlights

StrengthsRisks

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 153.10% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 95.62, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 131.04M shares, increasing 3.30% quarter-over-quarter.

Held by Joel Greenblatt

Star Investor Joel Greenblatt holds 168.46K shares of this stock.

Analyst Rating

Based on 24 analysts

Buy

Current Rating

33.500

Target Price

+89.91%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Apellis Pharmaceuticals Inc is 8.10, ranking 72 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 199.91M, representing a year-over-year decrease of 5.94%, while its net profit experienced a year-over-year decrease of 62.16%.

Score

Industry at a Glance

Previous score

8.10

Change



Financials

8.21

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.04

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.89

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.03

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.34

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Apellis Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Apellis Pharmaceuticals Inc is 7.55, ranking 64 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 95.62, which is 27.52% below the recent high of 121.93 and 122.68% above the recent low of -21.68.

Score

Industry at a Glance

Previous score

7.55

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 53/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Apellis Pharmaceuticals Inc is 7.74, ranking 96 out of 157 in the Pharmaceuticals industry. The average price target is 36.00, with a high of 55.00 and a low of 19.00.

Score

Industry at a Glance

Previous score

7.74

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 24 analysts

Buy

Current Rating

33.500

Target Price

+89.91%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Apellis Pharmaceuticals Inc

APLS

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Apellis Pharmaceuticals Inc is 5.53, ranking 138 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 19.70 and the support level at 15.54, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.85

Change

-0.32

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.119

Sell

RSI(14)

29.424

Sell

STOCH(KDJ)(9,3,3)

16.911

Neutral

ATR(14)

0.734

High Vlolatility

CCI(14)

-95.054

Neutral

Williams %R

95.748

Oversold

TRIX(12,20)

-0.883

Sell

StochRSI(14)

28.265

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

17.426

Sell

MA10

17.789

Sell

MA20

18.759

Sell

MA50

20.752

Sell

MA100

21.698

Sell

MA200

22.440

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Apellis Pharmaceuticals Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 116.63%, representing a quarter-over-quarter decrease of 1.58%. The largest institutional shareholder is The Vanguard, holding a total of 10.66M shares, representing 8.34% of shares outstanding, with 3.61% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Morningside Venture Investments, Ltd.

12.81M

Wellington Management Company, LLP

13.75M

+48.00%

Avoro Capital Advisors LLC

12.22M

The Vanguard Group, Inc.

Star Investors

9.97M

-1.65%

Morgan Stanley & Co. LLC

9.19M

+21.33%

Deep Track Capital LP

8.00M

+14.29%

BlackRock Institutional Trust Company, N.A.

5.34M

-2.51%

State Street Investment Management (US)

4.04M

+13.33%

Suvretta Capital Management, LLC

2.88M

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Apellis Pharmaceuticals Inc is 4.55, ranking 86 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.36. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Apellis Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.